TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release

Core Insights - TG Therapeutics (TGTX) is anticipated to report a year-over-year earnings increase driven by higher revenues, with a consensus EPS estimate of $0.32, reflecting a +700% change, and revenues expected at $136.04 million, up 85.2% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is crucial for stock movement; better-than-expected results could lead to a price increase, while a miss may result in a decline [2]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a positive Earnings ESP of +22.22% for TG Therapeutics, suggesting analysts have become more optimistic about the company's earnings prospects [12]. - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. Historical Performance - In the last reported quarter, TG Therapeutics had an expected EPS of $0.18 but reported only $0.03, resulting in a surprise of -83.33% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [14]. Industry Context - In comparison, Castle Biosciences, Inc. (CSTL) is expected to report a loss of $0.51 per share, indicating a year-over-year change of -264.5%, with revenues projected at $73.89 million, down 15.1% [18][19]. - Castle Biosciences has a Zacks Rank of 4 (Sell) and an Earnings ESP of 0%, making it challenging to predict an earnings beat [20].